Evidence map›Paper›PMID 36042351›Full record

ArticleCellular & molecular immunology2022

Treatment with a JAK1/2 inhibitor ameliorates murine autoimmune cholangitis induced by IFN overexpression.

Tihong Shao, Patrick S C Leung, Weici Zhang, Koichi Tsuneyama, William M Ridgway, Howard A Young, Zongwen Shuai, Aftab A Ansari, M Eric Gershwin

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular & molecular immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Liver diseases: epidemiology, causes, trends and predictions.Signal transduction and targeted therapy · 2025
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Targeting pathogenic CD8Nature communications · 2024
    Article
  16. Review
  17. Review
  18. Article
  19. Th1 cells inducing IFNγ response improves immunotherapy efficacy in gastric cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Tihong ShaoDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.ORCID http://orcid.org/0000-0001-7969-4794
Patrick S C LeungDivision of Rheumatology, Allergy, and Clinical Immunology, School of Medicine, University of California, Davis, CA, USA.
Weici ZhangDivision of Rheumatology, Allergy, and Clinical Immunology, School of Medicine, University of California, Davis, CA, USA.
Koichi TsuneyamaDepartment of Pathology and Laboratory Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
William M RidgwayDivision of Rheumatology, Allergy, and Clinical Immunology, School of Medicine, University of California, Davis, CA, USA.
Howard A YoungCenter for Cancer Research, National Cancer Institute-Frederick, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-3118-5111
Zongwen ShuaiDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Aftab A AnsariDivision of Rheumatology, Allergy, and Clinical Immunology, School of Medicine, University of California, Davis, CA, USA.ORCID http://orcid.org/0000-0003-4607-7268
M Eric GershwinDivision of Rheumatology, Allergy, and Clinical Immunology, School of Medicine, University of California, Davis, CA, USA. megershwin@ucdavis.edu.
University of California, Davis · USAnhui Medical University · CNFrederick National Laboratory for Cancer Research · USTokushima University · JP

Funding

Mechanistically based therapeutic strategies in murine primary biliary cholangitisR01DK123262 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GERSHWIN, MERRILL E · 2020 to 2023
$1.6M
BLRD VA I01 BX003821CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIDDK NIH HHS R01 DK123262
6 · The paper itself

Abstract

The interferon (IFN) signaling pathways are major immunological checkpoints with clinical significance in the pathogenesis of autoimmunity. We have generated a unique murine model named ARE-Del, with chronic overexpression of IFNγ, by altering IFNγ metabolism. Importantly, these mice develop an immunologic and clinical profile similar to patients with primary biliary cholangitis, including high titers of autoantibodies and portal inflammation. We hypothesized that the downregulation of IFN signaling pathways with a JAK1/2 inhibitor would inhibit the development and progression of cholangitis. To study this hypothesis, ARE-Del

Indexed as

Autoimmune DiseasesCholangitisJanus Kinase InhibitorsAnimalsAutoantibodiesCD8-Positive T-LymphocytesInflammationInterferon-gammaInterleukin-6MiceNitrilesPyrazolesPyrimidinesAutoantibodiesInterferon-gammaInterleukin-6Janus Kinase InhibitorsNitrilesPyrazolesPyrimidinesruxolitinibAutoimmunityInterferonsJanus Kinase InhibitorsPrimary biliary cholangitisRuxolitinib

Identifiers

PMID36042351
PMCPMC9508183
OpenAlexW4293561573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.